Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New Seroquel data show significant improvement in compliance and cognition in schizophrenia

24.05.2005


Patients with schizophrenia who are treated with the atypical antipsychotic SEROQUEL (Quetiapine) show significantly superior rates of treatment compliance compared to patients treated with other atypical and typical antipsychotics, according to new data presented today at the American Psychiatry Association (APA) meeting in Atlanta, USA. Additional data presented today also showed improved cognitive functioning for patients with schizophrenia who are treated with SEROQUEL.



The compliance study is one of the few to compare both atypical antipsychotics with each other as well as with typical antipsychotics in schizophrenia. The findings show SEROQUEL to have the highest compliance rate of both typicals and atypicals, which was significantly (P<0.05) greater than that of risperidone (6% greater) and olanzapine (4% greater). These are welcome results in a patient environment where up to 50% of patients fail to comply with their prescribed medication, leading to an increased risk of relapse. This can result in the need for rehospitalisation and potential for high socioeconomic costs.

"Compliance with medication is fundamental to a successful treatment outcome in schizophrenia. However, all too often patients have to struggle with medications that cause distressing side effects such as extrapyramidal symptoms (EPS), increased prolactin levels leading to galactorroeha and sexual dysfunction, which makes complying with treatment a challenge many patients find too difficult to overcome" commented Dr Michael Riedel from the Munich University Hospital, Germany. "It is critical therefore that medications are not only effective in treating symptoms but are also well tolerated, which is where atypicals such as SEROQUEL are able to offer patients an improved outcome."


Cognitive Function

Two other studies presented at this year’s APA meeting compared the cognitive benefits of SEROQUEL and risperidone in patients with schizophrenia, demonstrating improvements in cognitive function among Seroquel-treated patients:

  • In a randomized, double-blind study of 44 patients, both SEROQUEL and risperidone improved cognition in patients with schizophrenia over a 6-week period. However, SEROQUEL (at a mean dose of 566.7 mg/day) produced significantly greater improvements in working and verbal memory than risperidone (p<0.01 and p<0.05 vs risperidone, respectively), with a significantly lower incidence of EPS, a highly distressing treatment-induced side effect
  • In an 8-week, double-blind, flexible-dose, parallel study randomizing 673 patients with schizophrenia, cognitive benefits of SEROQUEL (mean modal dose of 530 mg/day) and risperidone were compared. Both medications were associated with overall improvements in cognitive functioning (p<0.01) versus baseline.

"It is encouraging to see that SEROQUEL appears to be at least as effective as risperidone in improving cognitive function while also demonstrating a superior side effect profile in terms of extrapyramidal symptoms" continued Dr. Riedel. "Cognitive impairment is a serious symptom but one which is sometimes perceived as less important than some other symptoms of schizophrenia, such as hallucinations. However, recent studies have found that cognitive function is directly related to many areas of social interaction, and can limit an individual from being able to benefit fully from rehabilitation programmes. That is why treating these symptoms effectively is so important."

SEROQUEL has been licensed for the treatment of schizophrenia since 1997 and is available in 82 countries for the treatment of this condition. Results of recent studies show that 600mg/day is an efficacious SEROQUEL dose in patients with schizophrenia. SEROQUEL is also licensed in 63 countries for the treatment of mania associated with bipolar disorder, including the US, Canada and several European countries. To date, over 8 million people have been treated with SEROQUEL worldwide.

Sarah Fraser | EurekAlert!
Further information:
http://www.shirehealth.com

More articles from Health and Medicine:

nachricht 'Exciting' discovery on path to develop new type of vaccine to treat global viruses
18.09.2017 | University of Southampton

nachricht A new approach to high insulin levels
18.09.2017 | Schweizerischer Nationalfonds SNF

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ultrafast snapshots of relaxing electrons in solids

Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!

When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...

Im Focus: Quantum Sensors Decipher Magnetic Ordering in a New Semiconducting Material

For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.

Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...

Im Focus: Fast, convenient & standardized: New lab innovation for automated tissue engineering & drug

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.

MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...

Im Focus: Silencing bacteria

HZI researchers pave the way for new agents that render hospital pathogens mute

Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...

Im Focus: Artificial Enzymes for Hydrogen Conversion

Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.

Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

I-ESA 2018 – Call for Papers

12.09.2017 | Event News

EMBO at Basel Life, a new conference on current and emerging life science research

06.09.2017 | Event News

IVAM’s LaserForum visits the Swiss canton of St. Gallen with the topic ultrashort pulse lasers

06.09.2017 | Event News

 
Latest News

Robust and functional – surface finishing by suspension spraying

19.09.2017 | Materials Sciences

The Wadden Sea and the Elbe Studied with Zeppelin, Drones and Research Ships

19.09.2017 | Earth Sciences

Digging sensors out of an efficiency hole

19.09.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>